Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ubrogepant. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCRL known ✓ | Q16602 | 20/20 | 1.00 |
| ▸ | RAMP1 | O60894 | 13/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ubrogepant SCHEMBL30596427 | 1.00 | CALCRL (1.00) | CALCRLRAMP1 | |
| Ubrogepant SCHEMBL22259356 | 1.00 | CALCRL (1.00) | CALCRLRAMP1 | |
| Ubrogepant SCHEMBL20784253 | 1.00 | CALCRL (1.00) | CALCRLRAMP1 | |
| Ubrogepant SCHEMBL31610892 | 1.00 | CALCRL (1.00) | CALCRLRAMP1 | |
| Ubrogepant SCHEMBL29373722 | 1.00 | CALCRL (1.00) | CALCRLRAMP1 | |
| Ubrogepant SCHEMBL16652449 | 0.99 | CALCRL (0.99) | CALCRLRAMP1 | |
| Ubrogepant SCHEMBL30416212 | 0.99 | CALCRL (0.99) | CALCRLRAMP1 | |
| Ubrogepant SCHEMBL16653012 | 0.99 | CALCRL (0.99) | CALCRLRAMP1 | |
| Ubrogepant SCHEMBL16652969 | 0.97 | CALCRL (0.94) | CALCRLRAMP1 | |
| SCHEMBL7030758 | 0.92 | CALCRL (0.85) | CALCRLRAMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190209478-A1 | TABLET FORMULATION FOR CGRP ACTIVE COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2019-07-11 | — | — | US | claimed |
| US-20190070161-A1 | FORMULATIONS FOR CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2019-03-07 | — | — | US | claimed |
| US-10117836-B2 | Tablet formulation for CGRP active compounds | MERCK SHARP & DOHME CORP. (US) | 2018-11-06 | — | — | US | claimed |
| EP-3102564-A1 | TABLET FORMULATION FOR CGRP-ACTIVE COMPOUNDS | Merck Sharp & Dohme Corp. (US) | 2016-12-14 | — | — | EP | claimed |
| US-20160346214-A1 | TABLET FORMULATION FOR CGRP ACTIVE COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2016-12-01 | — | — | US | claimed |
| US-20160346198-A1 | NOVEL DISINTEGRATION SYSTEMS FOR PHARMACEUTICAL DOSAGE FORMS | MERCK SHARP & DOHME CORP. (US) | 2016-12-01 | — | — | US | claimed |
| US-20160220552-A1 | FORMULATIONS FOR CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-08-04 | — | — | US | claimed |
| WO-2015119848-A1 | TABLET FORMULATION FOR CGRP-ACTIVE COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2015-08-13 | — | — | WO | claimed |
| EP-4737458-A2 | PROCESS FOR MAKING CGRP RECEPTOR ANTAGONISTS | Merck Sharp & Dohme LLC (US) | 2026-05-06 | — | — | EP | disclosed |
| CN-119386181-A | Application of CGRP receptor inhibitor in preparation of medicine for relieving or treating vitiligo | 上海市第一人民医院 | 2025-02-07 | — | — | CN | disclosed |
| US-12168004-B2 | Treatment of migraine | MERCK SHARP & DOHME LLC (US) | 2024-12-17 | — | — | US | disclosed |
| US-20240299369-A1 | TREATMENT OF MIGRAINE | MERCK SHARP & DOHME LLC | 2024-09-12 | — | — | US | disclosed |
| US-20240148745-A1 | COMPOUNDS FOR USE IN PROGRESSIVE MULTIPLE SCLEROSIS | FONDAZIONE CENTRO SAN RAFFAELE (IT) | 2024-05-09 | — | — | US | disclosed |
| US-11925709-B2 | Tablet formulation for CGRP active compounds | MERCK SHARP & DOHME CORP. (US) | 2024-03-12 | — | — | US | disclosed |
| US-20120122899-A1 | PIPERIDINONE CARBOXAMIDE AZAINDANE CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120122899-A1 | PIPERIDINONE CARBOXAMIDE AZAINDANE CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120122911-A1 | PIPERIDINONE CARBOXAMIDE AZAINDANE CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120122900-A1 | PIPERIDINONE CARBOXAMIDE AZAINDANE CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120122900-A1 | PIPERIDINONE CARBOXAMIDE AZAINDANE CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120122911-A1 | PIPERIDINONE CARBOXAMIDE AZAINDANE CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160220552-A1 | FORMULATIONS FOR CGRP RECEPTOR ANTAGONISTS | CALCR, CALCRL, VIPR1 | CALCRL 2/4885RAMP1 324/4885 |
| US-12168004-B2 | Treatment of migraine | ABCB1, GABARAP, GABARAPL2 | CALCRL 188/4885RAMP1 56/4885 |
| US-20160346214-A1 | TABLET FORMULATION FOR CGRP ACTIVE COMPOUNDS | CALCRL, CALCR, CALCA | CALCRL 1/4885RAMP1 23/4885 |
| US-20120122900-A1 | PIPERIDINONE CARBOXAMIDE AZAINDANE CGRP RECEPTOR ANTAGONISTS | CALCRL, CALCR, CNR2 | CALCRL 1/4885RAMP1 37/4885 |
| US-20190070161-A1 | FORMULATIONS FOR CGRP RECEPTOR ANTAGONISTS | CALCR, CALCRL, VIPR1 | CALCRL 2/4885RAMP1 324/4885 |
| US-20120122911-A1 | PIPERIDINONE CARBOXAMIDE AZAINDANE CGRP RECEPTOR ANTAGONISTS | CALCRL, CALCR, CNR2 | CALCRL 1/4885RAMP1 37/4885 |
| US-11925709-B2 | Tablet formulation for CGRP active compounds | CALCRL, CALCR, CALCA | CALCRL 1/4885RAMP1 20/4885 |
| US-20160346198-A1 | NOVEL DISINTEGRATION SYSTEMS FOR PHARMACEUTICAL DOSAGE FORMS | SBDS, SI, DSP | CALCRL 3803/4885RAMP1 4573/4885 |
| US-20240299369-A1 | TREATMENT OF MIGRAINE | ABCB1, GABARAP, GABARAPL2 | CALCRL 188/4885RAMP1 56/4885 |
| US-10117836-B2 | Tablet formulation for CGRP active compounds | CALCRL, CALCR, CALCA | CALCRL 1/4885RAMP1 23/4885 |
| US-20190209478-A1 | TABLET FORMULATION FOR CGRP ACTIVE COMPOUNDS | CALCRL, CALCR, CALCA | CALCRL 1/4885RAMP1 20/4885 |
| US-20120122899-A1 | PIPERIDINONE CARBOXAMIDE AZAINDANE CGRP RECEPTOR ANTAGONISTS | CALCRL, CALCR, CNR2 | CALCRL 1/4885RAMP1 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.